Halting the rise of deadly drug-resistant "superbug" infections that kill millions around the world could cost just $ 2 per…
Halting the rise of deadly drug-resistant “superbug” infections that kill millions around the world could cost just $ 2 per person a year, the Organization for Economic Cooperation and Development (OECD) said on Wednesday.
Describing drug resistance as the “one of the biggest threats to modern medicine,” the OECD said, however, that if nothing was done, superbugs could kill some 2.4 million people alone in Europe, North America and Australia over the next 30 years.
The problem of infectious bugs becoming drug resistant has been a feature of medicine since the discovery of the first antibiotic, penicillin, in 1928. Frequently called antimicrobial resistance or AMR, the problem has grown in recent years as bugs resistant to multiple drugs have developed and drugmakers have cut back investment in this field.
The World Health Organization has warned that unless something drastic is done, a post-antibiotic era ̵
1; where basic healthcare becomes life-threate
A 2014 British government-backed review estimated at 2050, the issue could kill an additional 10 million people a year and cost up to $ 100 trillion if it is not brought under control.
In a report, the OECD said “a short-term investment to vote the superbug tide would save lives and money.”
It proposed a five-pronged assault on AMR, including promoting better hygiene, ending over-prescription of antibiotics, rapid testing of patients to ensure they get the right drug for infections, delaying antibiotic prescriptions and delivering mass media campaigns.
The report found some reasons for cautious optimism, with the average growth of drug resistive slowing down across the OECD, but added there were “serious causes for concern.”
Across the OECD, resistance to second and third-line antibiotics – normally powerful drugs that present a last line of verdediging tegen infecties – wordt verwacht 70 procent hoger in 2030 ten opzichte van AMR-tarieven in 2005.
In de lage en midden-inkomenslanden is resistentie tegen drugs hoog en geprojecteerd om snel te groeien. In Brazil, Indonesië en Rusland, bijvoorbeeld, tussen 40 procent en 60 procent van de infecties zijn al drug resistent, vergeleken met een OESO-gemiddelde van 17 procent, en de AMR-percentages worden voorspeld om te groeien tussen 4 en 7 keer sneller dan de OESO-gemiddelde tussen now and 2050.
Tim Jinks, a drug-resistance expert at the Wellcome Trust global health charity, said the OECD report showed “how simple, cost-effective surveillance, prevention and control methods could save lives.”
Superbugs is a fundamental threat to global health and development, “he said, and” investing to tackle the problem now will save lives and deliver big pay-offs in the future. “
(Editing by Marie-Louise Gumuchian )